Skip to content

Development of a Cellular Biomarker for the Diagnosis and Treatment of Diabetic Foot Ulcers

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02329366
Enrollment
30
Registered
2014-12-31
Start date
2014-12-31
Completion date
2020-12-01
Last updated
2023-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot Ulcer, Type 2 Diabetes

Brief summary

This project aims to result in the identification of such markers, and the development of a feasible quantitative method of distinguishing between tissue that has the capacity to heal and tissue that does not, thus identifying a non-healing phenotype.

Detailed description

The goal of this project is to identify objective, quantitative biological and molecular markers that correlate with healing outcomes for diabetic foot ulcers (DFUs) using debrided tissue of patients with wounds. This project aims to result in the identification of such markers, and the development of a feasible quantitative method of distinguishing between tissue that has the capacity to heal and tissue that does not, thus identifying a non-healing phenotype. The ability to differentiate between healing and non-healing tissue at the onset of wound care will allow for the use of targeted therapies and earlier initiation of aggressive treatments where indicated.

Interventions

OTHERSpecimen Collection

. In this study, diabetic patients undergoing DFU debridement under the standard of care will be asked for their permission to collect the debrided tissue for use in scientific research.

Sponsors

Winthrop University Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Male or female, age ≥ 18 * Type 2 Diabetes * A break in the skin on the foot ≥ 0.5cm2 and is Grade 1 or 2 as defined by the Wagner grading system * Hemoglobin A1c ≥ 5.9% * Ability to provide written informed consent

Exclusion criteria

* Any experimental drugs taken orally or topically within 4 weeks of study entry * Malignant disease at/or in proximity to the DFU * Target wound of malignant origin * Failure to satisfy at least one inclusion criterion for one of the two study groups.

Design outcomes

Primary

MeasureTime frame
To identify objective, quantitative biological and molecular markers that correlate with healing outcomes for diabetic foot ulcers (DFUs) using debrided tissue of patients with woundsUndetermined

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026